Prognosis and duration

First line treatment

In the rare situation where an award is appropriate during treatment with standard chemotherapy, the award should last for the duration of treatment and then be reviewed.

Relapse

The five year survival of people who have had one relapse of lymphoma is 50%-60%; Needs are likely to be identified in this group, time limited awards with review are recommended to cover duration of treatment and recovery. 40-50% will die as a result of first relapse and are likely to have ongoing needs. Up to date medical evidence will be vital at any review of award.

People whose disease relapses a second or third time do less well and in this group long term or life awards are more appropriate – some may be terminally ill.

Long term side effects some years after successful treatment

Any needs arising from these are likely to be long term and life awards are recommended.

All information must be taken into account when considering the duration of disabling effects and the duration of disabling effects must be based on the particular circumstances of the individual claimant.

Amended February 2009